TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α)

被引：2
|
作者：
Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Ctr Leon Berard, Serv Cancerol Med, F-69373 Lyon, France
[6] Pfizer Inc, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4594
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors
    Motzer, R. J.
    Michaelson, M. D.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 301 - 301
  • [42] Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
    Rini, Brian I.
    Halabi, Susan
    Rosenberg, Jonathan E.
    Stadler, Walter M.
    Vaena, Daniel A.
    Archer, Laura
    Atkins, James N.
    Picus, Joel
    Czaykowski, Piotr
    Dutcher, Janice
    Small, Eric J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2137 - 2143
  • [43] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
  • [45] Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial)
    Mauge, L.
    Pereira, H.
    Gille, A. S.
    Bouaboula, M.
    Grine, A.
    Elaidi, R. T.
    Tartour, E.
    Fournier, L.
    Oudard, S.
    Helley, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S34 - S34
  • [46] Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
    Escudier, Bernard
    Bellmunt, Joaquim
    Negrier, Sylvie
    Bajetta, Emilio
    Melichar, Bohuslav
    Bracarda, Sergio
    Ravaud, Alain
    Golding, Sophie
    Jethwa, Sangeeta
    Sneller, Vesna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2144 - 2150
  • [47] Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
    Pruis, Sil-ling
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Tan, Min Han
    Wu, David Bin-Chia
    Ng, Kwong
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) : 126 - 133
  • [48] Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.
    Shaheen, P. E.
    Tamaskar, I. R.
    Salas, R. N.
    Rini, B. I.
    Garcia, J.
    Wood, L.
    Dreicer, R.
    Bukowski, R. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [49] Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
    Rini, Brian I.
    Bellmunt, Joaquim
    Clancy, Jill
    Wang, Kongming
    Niethammer, Andreas G.
    Hariharan, Subramanian
    Escudier, Bernard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 752 - +
  • [50] Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α)
    Cella, D.
    Li, J. Z.
    Cappelleri, J. C.
    Bushmakin, A.
    Charbonneau, C.
    Kim, S. T.
    Chen, I.
    Michaelson, M. D.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345